Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd., a leading biopharmaceutical company based in China, focuses on innovative drug discovery and development. Founded in 2015, the company has rapidly established itself in the biotechnology sector, with its headquarters in Beijing and operational reach across major regions in China. Specialising in monoclonal antibodies and gene editing technologies, Biocytogen is renowned for its unique animal models that facilitate advanced preclinical research. The company’s commitment to innovation has positioned it as a key player in the global biopharmaceutical landscape, with notable achievements in therapeutic development and collaborations with various research institutions. With a strong emphasis on quality and scientific excellence, Biocytogen continues to drive advancements in the industry, contributing significantly to the future of healthcare solutions.
DitchCarbon Score
How does Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s score of 32 is higher than 95% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.'s reported carbon emissions
In 2023, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. reported total carbon emissions of approximately 23,506,310 kg CO2e, with emissions distributed across various scopes. Specifically, Scope 1 emissions accounted for about 23,506,310 kg CO2e, while Scope 2 emissions were minimal at 240 kg CO2e. Notably, Scope 3 emissions, primarily from purchased goods and services, reached approximately 57,347,000 kg CO2e. Comparatively, in 2022, the company recorded total emissions of about 19,472,490 kg CO2e, with Scope 1 and Scope 2 emissions each contributing equally to this total. The significant increase in emissions from 2022 to 2023 highlights the company's growing operational footprint. Despite these figures, Biocytogen has not publicly disclosed specific reduction targets or initiatives aimed at mitigating their carbon footprint. The absence of formal climate pledges or science-based targets suggests that while the company is aware of its emissions, it may not yet have established a comprehensive strategy for emissions reduction. As the industry increasingly prioritises sustainability, Biocytogen's future commitments will be crucial in aligning with global climate goals.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 19,472,490 | 00,000,000 |
| Scope 2 | 19,472,490 | 000 |
| Scope 3 | 19,472,490 | 000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
